Monoclonal antibodies

#Antibodies #Clinical trials #Data #Monoclonal antibodies

AstraZeneca Imfinzi combination effective with non-small cell lung cancer 

Results from the large, randomised COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had… Read More

#News

#Covid-19 #Healthcare #Monoclonal antibodies

First monoclonal antibody treatment for Covid-19 approved for UK 

Following a thorough review of evidence carried out by the Medicines and Healthcare products Regulatory Agency (MHRA) and recommendation by the Commission on Human Medicines (CHM), the UK government’s independent expert scientific advisory body, the MHRA has approved Ronapreve as the first monoclonal antibody combination product indicated for use in the… Read More

#Covid-19 #News #Trending News

#Antibodies #Immunology / Virology & Vaccines #Malaria #Monoclonal antibodies

Monoclonal antibody prevents malaria in NIH trial 

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health (NIH) safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria… Read More

#News #Trending News

#Antigen #Drug discovery #Immunology / Virology & Vaccines #Monoclonal antibodies

How to get your drug to market faster

The pressure to take your drug to market faster is increasing. To achieve a successful journey to the first clinical trial phase in the fastest time possible, Eppendorf has identified three key elements that it is addressing in an eBook.  Comply with audit requirements and relevant certifications  Drive process efficiencies… Read More

#Editor's Choice #News